Data / Research funding / Biodefense
Biodefense: 1,796 NIH awards ($1.2B) to 456 organizations
1,796 NIH awards ($1.2B) in the NIH spending category Biodefense, to 456 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 1,796 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Center for Viral Systems Biology (CViSB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,438,330 | February 1, 2018 | January 31, 2028 | ANDERSEN, KRISTIAN GRAUGAARD | reporter.nih.gov |
| Metabolic determinants of Mtb virulence, vulnerability and variation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,485,680 | May 1, 2025 | April 30, 2027 | MOODY, DAVID BRANCH | reporter.nih.gov |
| Protective immunity following dengue virus natural infections and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,429,941 | July 29, 2015 | July 31, 2030 | HARRIS, EVA | reporter.nih.gov |
| Trusted Training: Improving Health and Safety Through an All-Hazard Training Approach | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $13,355,376 | September 1, 1992 | May 31, 2030 | FITCH, ASHLEE | reporter.nih.gov |
| Successful Clinical Response In Pneumonia Therapy (SCRIPT) Systems Biology Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,773,513 | January 17, 2018 | December 31, 2027 | WUNDERINK, RICHARD G | reporter.nih.gov |
| FEND for TB supplement to accelerate BLINK X development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $8,340,332 | June 4, 2020 | May 31, 2025 | ELLNER, JERROLD J. | reporter.nih.gov |
| Augmenting Scientific Discovery and Research Infrastructure in the UAB Regional Biocontainment Laboratory (SEBLAB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $7,660,000 | September 23, 2021 | February 28, 2025 | LEAL, SIXTO MANUEL | reporter.nih.gov |
| Administrative Supplements for NIAID Regional Biocontainment Laboratories (RBL) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $7,369,853 | September 23, 2021 | February 28, 2025 | ALEM, FARHANG | reporter.nih.gov |
| Facility Upgrade for the New England Regional Biosafety Laboratory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $7,162,679 | August 22, 2022 | February 28, 2025 | TELFORD, SAM R | reporter.nih.gov |
| Development of a COVID-19 Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,733,518 | September 1, 2020 | October 31, 2023 | REED, STEVEN | reporter.nih.gov |
| TNPRC Regional Biocontainment Laboratory Upgrade for Capacity Building | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,714,363 | September 23, 2021 | February 28, 2025 | RAPPAPORT, JAY | reporter.nih.gov |
| Administrative Supplement for Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,659,737 | August 22, 2022 | February 28, 2025 | DUPREX, WILLIAM PAUL | reporter.nih.gov |
| Administrative supplement to Duke G20 award | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,594,615 | September 23, 2021 | February 28, 2025 | STAATS, HERMAN F | reporter.nih.gov |
| Facility and Building System Upgrades Support for the Howard T. Ricketts Biocontainment Laboratory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,593,067 | September 16, 2021 | February 28, 2025 | ADAMS, ERIN JUNE | reporter.nih.gov |
| Regional Biocontainment Laboratory (RBL) Upgrade for Colorado State University (CSU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,493,184 | September 23, 2021 | February 28, 2025 | DOBOS, KAREN MARIE | reporter.nih.gov |
| Structural Genomics Centers for Infectious Diseases: SARS-CoV-2 Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $5,706,284 | September 1, 2017 | August 31, 2022 | SATCHELL, KARLA | reporter.nih.gov |
| Improvements to the Regional Biocontainment Research Facilities at the University of Missouri | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $5,667,997 | September 23, 2021 | February 28, 2025 | LORSON, CHRISTIAN L. | reporter.nih.gov |
| STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $5,288,246 | September 1, 2017 | August 31, 2021 | MYLER, PETER | reporter.nih.gov |
| Supplement to G20AI67347 to complete critical upgrades to the Rutgers RBL | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $5,241,770 | August 22, 2022 | February 29, 2024 | ALLAND, DAVID | reporter.nih.gov |
| UTHSC RBL Administrative Supplement For Antiviral Discovery & Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $5,233,648 | September 15, 2021 | February 28, 2025 | JONSSON, COLLEEN B | reporter.nih.gov |
| Evaluation of an OMV-adjuvanted Chimeritrope Vaccine against Lyme Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $4,961,891 | September 30, 2018 | September 29, 2023 | MORICI, LISA | reporter.nih.gov |
| The Historically Black Colleges/Universities and Communities Worker Health and Safety Training Program | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $4,913,625 | September 15, 2000 | May 31, 2025 | WRIGHT, BEVERLY L | reporter.nih.gov |
| Development of the INI-4001 and INI-2002 adjuvants within the context of a vaccine to prevent Lyme disease. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $4,583,801 | September 30, 2018 | September 29, 2024 | EVANS, JAY | reporter.nih.gov |
| Upgrading infectious disease research facilities at University of Louisville RBL | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $4,553,002 | August 22, 2022 | February 28, 2025 | PALMER, KENNETH E | reporter.nih.gov |
| Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation studies to Evaluate the Safety and Efficacy of SPI-1005 in Moderate and Severe COVID-19 Patients | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $4,174,965 | April 6, 2021 | April 5, 2023 | KIL, JONATHAN | reporter.nih.gov |
| ERMES EVALUATION OF RADIOMITIGATIVE EFFICACY AND SAFETY OF BP-C2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $4,068,475 | May 1, 2020 | April 30, 2023 | PIGAREV, SERGEI | reporter.nih.gov |
| DMID REGULATORY AFFAIRS SUPPORT | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $3,723,712 | July 1, 2015 | June 30, 2022 | BUTLER, SANDRA | reporter.nih.gov |
| Adjuvant Development Program in the context of vaccines to protect against Y. pestis and Shigella. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $3,532,934 | September 30, 2018 | September 29, 2023 | ERNST, ROBERT | reporter.nih.gov |
| Task B08: Development and Use of a Non-Human Primate Model of SARS-CoV-2 Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $3,192,083 | September 21, 2020 | June 14, 2023 | THOMPSON, KAREN | reporter.nih.gov |
| DECODING THE INTERACTIONS BETWEEN T CELL RECEPTORS AND PEPTIDE-MHC | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,185,903 | June 20, 2018 | September 21, 2025 | THOMAS, PAUL G. | reporter.nih.gov |
| Outer Membrane Biogenesis: New Antibiotic Targets | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,022,068 | December 15, 2008 | April 30, 2029 | KAHNE, DANIEL | reporter.nih.gov |
| Recombinant West Nile Virus Vaccine Adjuvanted with SLA-LSQ Optimize Formulation of VSA Adjuvant | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $2,997,218 | July 5, 2022 | July 5, 2025 | CLEMENTS, DAVID | reporter.nih.gov |
| Increasing Availability of Emulsion Adjuvants via Synthetic Biology | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $2,996,311 | August 30, 2022 | August 29, 2025 | KEMPINSKI, CHASE | reporter.nih.gov |
| Establishing a Gram-Negative Permeation Rule Set Leveraging a Unique Small Molecule Library | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,971,055 | August 22, 2018 | July 31, 2024 | BOYD, STEVEN ARMEN | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $2,887,773 | July 1, 2020 | May 31, 2022 | TOMMASI, RUBEN | reporter.nih.gov |
| Natural Killer Cell Tolerance to Self | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,863,003 | March 1, 2017 | February 28, 2027 | YOKOYAMA, WAYNE M. | reporter.nih.gov |
| Bioinformatics Framework for Wastewater-based Surveillance of Infectious Diseases | NIH | National Library of Medicine | 2021 to 2022 | $2,817,521 | June 3, 2019 | May 31, 2024 | SCOTCH, MATTHEW | reporter.nih.gov |
| Non-canonical functions of neutrophils | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,816,555 | June 16, 2022 | May 31, 2027 | HIDALGO, ANDRES | reporter.nih.gov |
| Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,754,890 | April 1, 2015 | September 1, 2022 | KHADER, SHABAANA A. | reporter.nih.gov |
| Adjuvant Development in the context of a vaccine to protect against tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,722,493 | September 30, 2018 | September 29, 2023 | PETROVSKY, NIKOLAI | reporter.nih.gov |
| Development of Inhaled CPZEN-45 For Tuberculosis Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,694,338 | March 1, 2019 | February 28, 2025 | SEVERYNSE-STEVENS, DIANA M | reporter.nih.gov |
| Safety and Immunogenicity of H3N2 M2SR monovalent influenza vaccine in older subjects | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,605,499 | August 25, 2020 | May 31, 2023 | BILSEL, PAMUK | reporter.nih.gov |
| Development of an Anthrax Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $2,562,540 | September 25, 2008 | July 7, 2021 | PARK, SUKJOON | reporter.nih.gov |
| Predictive Models for Small-Molecule Accumulation in Gram-Negative Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,478,608 | August 10, 2018 | July 31, 2024 | TAN, DEREK S | reporter.nih.gov |
| Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,406,319 | December 1, 2017 | November 30, 2025 | HORWITZ, MARCUS AARON | reporter.nih.gov |
| Optimization and preclinical development of a TB Multiple Antigen Presenting System (MAPS) vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,298,018 | December 15, 2017 | November 30, 2023 | MALLEY, RICHARD | reporter.nih.gov |
| Predictive Guidelines for Penetrance and Discovery of Broad-Spectrum Antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,281,750 | February 6, 2018 | January 31, 2024 | HERGENROTHER, PAUL | reporter.nih.gov |
| SFTSV nonstructural protein NSs-mediated immunopathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,260,994 | July 1, 2018 | June 30, 2024 | JUNG, JAE U | reporter.nih.gov |
| Develop a candidate subunit vaccine for Powassan Virus and West Nile virus adjuvanted with Alhydroxiquim-II | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $2,258,969 | September 30, 2018 | September 29, 2023 | DAVID, SUNIL | reporter.nih.gov |
| CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS) | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $2,227,740 | April 1, 2014 | August 1, 2022 | GARCIA-SASTRE, ADOLFO | reporter.nih.gov |
| Diagnostics via Rapid Enrichment, Identification, and Phenotypic Antibiotic Susceptibility Testing of Pathogens from Blood. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,219,076 | May 11, 2018 | April 30, 2024 | WU, BETTY B | reporter.nih.gov |
| Optimization of efflux avoidance and inhibition for antibiotic development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,205,402 | February 7, 2018 | January 31, 2025 | ZGURSKAYA, HELEN I | reporter.nih.gov |
| Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,175,842 | August 10, 2018 | July 31, 2024 | BULITTA, JURGEN BERND | reporter.nih.gov |
| Point-of-care antimicrobial susceptibility testing based on simultaneous tracking of multi-phenotypic features of single bacterial cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,159,472 | July 25, 2018 | June 30, 2025 | WANG, SHAOPENG | reporter.nih.gov |
| Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negativebacterial infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,153,664 | March 22, 2019 | April 30, 2024 | PERLIN, DAVID S | reporter.nih.gov |
| Task A44: Ferret Models for the Evaluation of Universal Influenza Vaccines and Vaccine Strategies | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $2,150,482 | August 13, 2020 | May 9, 2022 | WALTERS, KEVIN | reporter.nih.gov |
| Exploiting Riboswitch Sensors to Reveal Antibiotics Uptake and Retention in Gram Negative Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,138,415 | February 19, 2018 | January 31, 2024 | BREAKER, RONALD R | reporter.nih.gov |
| Dynamic regulatory network models of human response to influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,128,800 | August 17, 2020 | October 3, 2022 | MARAZZI, IVAN | reporter.nih.gov |
| Short and long term outcomes of doxycycline versus TMP-SMX for SSTI treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,085,900 | July 16, 2018 | June 30, 2025 | MILLER, LOREN G. | reporter.nih.gov |
| Multidisciplinary Training in Microbial Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,054,812 | September 1, 1988 | June 30, 2030 | BRADLEY, PETER JOHN | reporter.nih.gov |
| Immunization against filamentous bacteriophages to prevent bacterial infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,033,928 | June 8, 2018 | May 31, 2025 | EVANS, JAY T. | reporter.nih.gov |
| Fecal Microbiota Transplant for C. difficile Infection in Solid Organ Transplant Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,027,511 | September 15, 2018 | August 31, 2023 | SAFDAR, NASIA | reporter.nih.gov |
| Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,019,810 | August 20, 2018 | March 31, 2024 | LINKE, LYNDSEY | reporter.nih.gov |
| A new class of broad-spectrum antibacterials for treating MDR infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,000,000 | May 1, 2020 | April 30, 2023 | TESTA, CHARLES | reporter.nih.gov |
| Preclinical development of an immunomodulatory agent capable of mitigating SARS-CoV-2 virus related hypercytokinemia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,000,000 | March 6, 2021 | February 29, 2024 | CRAIGO, JODI K | reporter.nih.gov |
| Experimental Gonococcal Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,000,000 | January 1, 2015 | June 30, 2023 | AUCI, DOMINICK | reporter.nih.gov |
| Immunotherapy of MRSA Osteomyelitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,000,000 | May 12, 2021 | April 30, 2023 | AMAN, M JAVAD | reporter.nih.gov |
| eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,000,000 | June 1, 2020 | May 31, 2023 | GARCIA, JOE G. N. | reporter.nih.gov |
| Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,000,000 | August 1, 2019 | July 31, 2024 | ROEMER, TERRY | reporter.nih.gov |
| Rapid Point-of-Care RNA Diagnostic for Dengue Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,999,598 | March 15, 2019 | July 31, 2025 | CHO, HYUNDAE | reporter.nih.gov |
| Strain-Independent Therapeutic Antibodies for Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,999,271 | July 1, 2014 | January 31, 2023 | KAUVAR, LAWRENCE MICHAEL | reporter.nih.gov |
| Pre-IND Development of an Arenavirus Antiviral | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,997,148 | February 10, 2014 | February 29, 2024 | HENKEL, GREGORY WILLIAM | reporter.nih.gov |
| Teixobactin Development for Anthrax | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,989,172 | June 15, 2020 | May 31, 2024 | HUGHES, DALLAS | reporter.nih.gov |
| ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,988,078 | June 22, 2020 | June 30, 2025 | TARRAN, ROBERT | reporter.nih.gov |
| Adjuvant Development within the context of a vaccine to protect against B. pertussis for use in newborns. | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $1,986,305 | September 30, 2018 | September 29, 2023 | LEVY, OFER | reporter.nih.gov |
| Pre-Clinical Development of a Intranasal Bivalent gD2/gB2 HSV-2 Mucosal Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,982,258 | March 1, 2017 | July 31, 2025 | TRABBIC, KEVIN | reporter.nih.gov |
| Biofilm disrupting antibody to treat respiratory and musculoskeletal infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,980,222 | September 1, 2020 | August 31, 2023 | KAUVAR, LAWRENCE MICHAEL | reporter.nih.gov |
| Rapid Low Cost Phenotypic Antibiotic Susceptibility Testing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,975,326 | February 7, 2017 | March 31, 2023 | RHODES, PAUL | reporter.nih.gov |
| Development of an automated IVD for the ultra-sensitive, direct, molecular detection of Borrelia for early Lyme Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,972,995 | June 15, 2020 | May 31, 2024 | SINGER, ALON | reporter.nih.gov |
| Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,964,220 | July 1, 2016 | December 31, 2023 | EBETINO, FRANK H. | reporter.nih.gov |
| Mechanisms of regulation of lymphocyte migration by actin cytoskeletal effectors | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,960,970 | September 23, 2022 | July 31, 2027 | JACOBELLI, JORDAN | reporter.nih.gov |
| Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,959,337 | February 16, 2018 | February 29, 2024 | REDER, JAKE | reporter.nih.gov |
| A Novel Recombinant Protein for Mitigating Acute Radiation Injury | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,948,766 | June 10, 2014 | March 31, 2024 | CHAUNG, WAYNE | reporter.nih.gov |
| Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,938,759 | April 21, 2016 | May 31, 2024 | CHAKRAVARTY, SUMANA | reporter.nih.gov |
| Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,929,790 | September 1, 2019 | August 31, 2025 | WEINER, DAVID B. | reporter.nih.gov |
| Therapy and Prophylaxis for Genital Tract Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,915,331 | February 1, 2013 | April 30, 2023 | AUCI, DOMINICK | reporter.nih.gov |
| Antibody-based Protection against Flavivirses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,903,581 | September 15, 2007 | March 13, 2024 | DIAMOND, MICHAEL S | reporter.nih.gov |
| A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,887,207 | July 1, 2020 | June 30, 2024 | FANGER, GARY | reporter.nih.gov |
| Development of a new TLR4 agonist for the treatment of Allergic Rhinitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,836,453 | September 1, 2021 | August 31, 2023 | KHALAF, JUHIENAH | reporter.nih.gov |
| A dual function TB subunit vaccine designed for non-interference with BCG and post-exposure activity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,803,446 | December 1, 2017 | November 30, 2023 | MORTENSEN, RASMUS SKAARUP | reporter.nih.gov |
| Pathogenesis of Fever in Man | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,801,666 | December 1, 1986 | August 31, 2026 | DINARELLO, CHARLES ANTHONY | reporter.nih.gov |
| Rapid, Point-of-Care Diagnostics for Hepatitis C Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,799,981 | August 12, 2022 | August 12, 2025 | UNGEWITTER, ERICA | reporter.nih.gov |
| A universal, scale-independent artificial intelligence-based platform for manufacturing high titer bacteriophage preparations for clinical applications | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,797,717 | August 16, 2021 | August 15, 2025 | RUZICKA, MEL | reporter.nih.gov |
| Regulation of antibody secreting cell (ASC) homeostasis by Ufbp1. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,796,247 | September 24, 2020 | August 31, 2025 | SINGH, NAGENDRA | reporter.nih.gov |
| Multivalent DNA vaccine-mediated protection against Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,773,692 | November 23, 2017 | October 31, 2024 | WEINER, DAVID B. | reporter.nih.gov |
| Development of Therapeutic Products for Marburg Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,749,368 | May 17, 2021 | December 16, 2025 | AMAN, M JAVAD | reporter.nih.gov |
| Development of highly potent human monoclonal for RSV immuno-prophylaxis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,748,888 | January 15, 2018 | June 30, 2023 | ZEITLIN, LARRY | reporter.nih.gov |
| Training in Immunological Mechanisms | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,717,051 | August 1, 2016 | July 31, 2026 | CROFT, MICHAEL | reporter.nih.gov |
| Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,679,440 | December 15, 2021 | December 14, 2022 | CAUDLE, ROB | reporter.nih.gov |
| A Novel Th17-inducing Mucosal Vaccine for Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,676,215 | September 9, 2020 | September 2, 2022 | KHADER, SHABAANA A. | reporter.nih.gov |
| Mechanisms of Radiation-induced Vascular Endothelial Cell Injury and Its Correction | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,647,608 | June 7, 2017 | May 31, 2024 | BRENNER, MAX | reporter.nih.gov |
| A method for the culture-free discovery and host affiliation of novel viruses from metagenomic samples | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,640,758 | February 8, 2021 | January 31, 2023 | LIACHKO, IVAN | reporter.nih.gov |
| Host-pathogen interactions during hospital adaptation of MRSA | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,620,818 | September 1, 2019 | August 31, 2024 | SHOPSIN, BO | reporter.nih.gov |
| Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,619,208 | January 16, 2018 | December 31, 2023 | FOX, CHRISTOPHER B | reporter.nih.gov |
| DYNAMICS AND TUNING OF THE MHC II PRESENTED PEPTIDOME | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,603,685 | September 19, 2018 | August 31, 2025 | SANTAMBROGIO, LAURA | reporter.nih.gov |
| The Role of Casual Contact and Migration in XDR TB Transmission in South Africa: a Geospatial, Genomic and Social Network Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,594,622 | January 17, 2018 | December 31, 2024 | SHAH, NIPPIE SARITA | reporter.nih.gov |
| Understanding the functional role of Myeloid Derived Suppressor cells in tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,589,530 | July 6, 2020 | September 2, 2022 | KHADER, SHABAANA A. | reporter.nih.gov |
| Structure and Function of C. Difficile Toxins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,584,842 | May 15, 2018 | April 30, 2024 | DONG, MIN | reporter.nih.gov |
| Foam cells as drug targets in tuberculosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,575,009 | August 1, 2019 | June 30, 2025 | GENNARO, MARIA LAURA | reporter.nih.gov |
| OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,569,974 | April 19, 2018 | March 31, 2023 | WOODS, ERIK J. | reporter.nih.gov |
| Molecular Mechanisms of Microbial Pathogenesis Training Program | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,561,697 | September 30, 1998 | August 31, 2025 | CARRUTHERS, VERNON BRUCE | reporter.nih.gov |
| Systems Biology of Mumps Vaccine Response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,555,746 | June 15, 2018 | May 31, 2025 | KENNEDY, RICHARD B | reporter.nih.gov |
| Characterization of Genomics and Metabolomics among Individuals Highly-Exposed, but resistant to Mtb Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,552,036 | July 1, 2018 | June 30, 2025 | GANDHI, NEEL RAJNIKANT | reporter.nih.gov |
| Transcriptomic Signatures of Influenza Vaccine Responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,540,548 | January 17, 2018 | December 31, 2024 | POLAND, GREGORY A. | reporter.nih.gov |
| Rapid Differential Diagnosis of COVID-19 and Common Respiratory Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,531,885 | February 11, 2021 | November 30, 2023 | PAMULA, VAMSEE K. | reporter.nih.gov |
| Development of Novel Proteins Synthesis Inhibitors for MDR Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,526,635 | July 6, 2010 | February 29, 2024 | LEE, RICHARD E. | reporter.nih.gov |
| Dynamic Control of Innate Antiviral Immunity in Skin Homeostasis and Inflammation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,525,958 | May 11, 2018 | April 30, 2024 | ZHANG, JENNIFER YUNYAN | reporter.nih.gov |
| Role of mycobacterial dynamin-like proteins in the biogenesis of membrane vesicles, and host-pathogen interactions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,521,407 | July 1, 2021 | June 30, 2026 | RODRIGUEZ, GLORIA MARCELA | reporter.nih.gov |
| Molecular mechanism of NLRP3 inflammasome activation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,520,560 | May 4, 2020 | April 30, 2026 | HE, YUAN | reporter.nih.gov |
| Dynamics of the protective vaccine-induced human influenza neuraminidase B cell response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,517,506 | September 16, 2019 | August 31, 2025 | KOBIE, JAMES J | reporter.nih.gov |
| Development of novel penems for drug-resistant tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,504,818 | January 3, 2018 | December 31, 2024 | TOWNSEND, CRAIG ARTHUR | reporter.nih.gov |
| Microscale models of inflammation and its resolution | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,504,556 | April 25, 2018 | March 31, 2024 | BEEBE, DAVID J | reporter.nih.gov |
| RAPID POINT OF CARE TESTS FOR TUBERCULOSIS | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,500,000 | August 12, 2021 | August 8, 2024 | ZHOU, YAN | reporter.nih.gov |
| INNOVATIVE PEDIATRIC ORAL FORMULATIONS FOR SECOND LINE TUBERCULOSIS DRUGS | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,499,998 | September 3, 2021 | BRAUN, NIKOLAI | reporter.nih.gov | |
| Siderophore Inhibitors for Tuberculosis that Block Mycobactin Biosynthesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,499,516 | April 25, 2018 | March 31, 2023 | ALDRICH, COURTNEY C | reporter.nih.gov |
| THERAPEUTICS FOR EMERGING HUMAN ENTEROVIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $1,499,422 | July 1, 2022 | June 30, 2025 | SAR, KANDYMA | reporter.nih.gov |
| ADVANCEMENT OF POTENT BROAD SPECTRUM ENTEROVIRUS THERAPEUTICS | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $1,499,249 | July 1, 2022 | June 30, 2025 | PERSSON, INGRID | reporter.nih.gov |
| Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,497,909 | May 2, 2018 | April 30, 2025 | NIELSEN, KARIN | reporter.nih.gov |
| Improving Influenza Vaccination Delivery Across a Health System by the Electronic Health Records Patient Portal | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,495,366 | January 16, 2018 | December 31, 2023 | SZILAGYI, PETER G | reporter.nih.gov |
| Host-directed therapy of tuberculosis: Rescuing macrophages and enhancing their activation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,495,330 | September 24, 2018 | August 31, 2023 | NATHAN, CARL FRANCIS | reporter.nih.gov |
| Development of validated probes for the bacterial type III secretion system | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,491,580 | June 1, 2019 | May 31, 2025 | STONE, VICTORIA AUERBUCH | reporter.nih.gov |
| Antibody mediated protective immunity against cholera | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,483,473 | September 14, 2018 | August 31, 2024 | HARRIS, JASON B | reporter.nih.gov |
| Pathways of vertical Zika virus transmission in nonhuman primate pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,478,500 | April 25, 2018 | March 31, 2025 | MOHR, EMMA L | reporter.nih.gov |
| Genomics of S. Aureus Colonization after Initial and Recurrent Skin Infections and the Impact of Antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,478,000 | August 16, 2018 | July 31, 2025 | DAVID, MICHAEL ZDENEK | reporter.nih.gov |
| Mapping polymicrobial interactions that modulate antibiotic persistence | NIH | National Institute of General Medical Sciences | 2021 | $1,476,000 | September 20, 2021 | August 31, 2024 | MOK, WENDY W.K. | reporter.nih.gov |
| Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,473,115 | March 12, 2020 | February 28, 2023 | AMAN, M JAVAD | reporter.nih.gov |
| Identifying individuals at risk of progression to active tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,471,016 | February 22, 2018 | January 31, 2025 | CATANZARO, ANTONINO | reporter.nih.gov |
| Rapid immunoassay for diagnosis of coccidioidomycosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $1,469,691 | September 30, 2022 | September 29, 2025 | BURNHAM MARUSCICH, AMANDA | reporter.nih.gov |
| Evolution of drug resistance in Candida glabrata | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,468,693 | December 1, 2018 | May 31, 2023 | SHERLOCK, GAVIN J | reporter.nih.gov |
| Thermostabilized Subunit Glycoprotein Vaccine Platform: Immune Characterization of an Emulsified Adjuvant with SARS-CoV-2 Spike Protein and EBOV GP | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,466,410 | December 17, 2020 | November 30, 2023 | DONINI, OREOLA | reporter.nih.gov |
| Precision immunoprofiling to reveal diagnostic biomarkers of latent TB infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,466,090 | September 5, 2019 | August 31, 2025 | BAILEY, RYAN C | reporter.nih.gov |
| Sequelae of Lassa Fever | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,462,104 | February 9, 2018 | January 31, 2025 | PAESSLER, SLOBODAN | reporter.nih.gov |
| Murine Typhus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,453,516 | September 1, 1982 | May 31, 2025 | RAHMAN, MOHAMMED SAYEEDUR | reporter.nih.gov |
| Prevalence, Pathogenesis, and Persistence of Lassa Fever in West Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,452,994 | February 7, 2018 | January 31, 2024 | WOHL, DAVID A | reporter.nih.gov |
| Dissecting the genetic basis of protective immunity to tuberculosis in diverse hosts | NIH | National Institute of General Medical Sciences | 2021 | $1,449,000 | September 20, 2021 | August 31, 2024 | SMITH, CLARE MARGARET | reporter.nih.gov |
| Development of Monoclonal Antibody Therapeutics for Anthrax | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,448,422 | September 1, 2008 | August 31, 2012 | JOHNSON, VIRGINIA G. | reporter.nih.gov |
| Development of Antibiotic Adjuvants for Gram-Negative Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,446,751 | September 21, 2018 | August 31, 2024 | MELANDER, CHRISTIAN COREY | reporter.nih.gov |
| A "Culture" Shift: Integrated Bacterial Screening and Antibacterial Susceptibility Test on Microfluidic Digital Array for Bloodstream Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,434,371 | January 23, 2018 | December 31, 2023 | WANG, TZA-HUEI JEFF | reporter.nih.gov |
| Structural Vaccinology and Design of Novel Imunogens for Malaria Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,430,568 | February 1, 2018 | January 31, 2024 | GOLDBERG, DANIEL E. | reporter.nih.gov |
| Antibacterial inhibitors of RnpA | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,428,372 | May 7, 2018 | April 30, 2024 | DUNMAN, PAUL M. | reporter.nih.gov |
| Genetic regulation and immunological function of ERAP2 haplotypes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,417,074 | June 15, 2018 | May 31, 2024 | YE, CHUN JIMMIE | reporter.nih.gov |
| Development of non-toxic amphotericin B derivatives targeting invasive fungal infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,416,753 | June 8, 2018 | May 31, 2025 | BURKE, MARTIN D | reporter.nih.gov |
| Microbial ecology of the inflamed intestine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,411,946 | September 24, 2018 | August 31, 2024 | AHMER, BRIAN M | reporter.nih.gov |
| Alveolus as Incubator: Functional Genomic Dissection of the Host Response to SARS-CoV-2 Infection. | NIH | National Institute of General Medical Sciences | 2021 | $1,410,500 | September 20, 2021 | August 31, 2024 | ORVEDAHL, ANTHONY W | reporter.nih.gov |
| Regulation of CD8+ T cell immunity to tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,409,160 | August 2, 2013 | April 30, 2024 | BEHAR, SAMUEL M | reporter.nih.gov |
| Design and Analysis of Vaccine Trials for Emerging Infectious Disease Threats | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,403,064 | August 15, 2018 | July 31, 2025 | DEAN, NATALIE EXNER | reporter.nih.gov |
| Functional characterization of CARD9 genetic variants in fungal immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,396,562 | February 8, 2018 | January 31, 2024 | XAVIER, RAMNIK J | reporter.nih.gov |
| Germline targeting influenza immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,394,075 | August 10, 2017 | July 31, 2024 | NEMAZEE, DAVID | reporter.nih.gov |
| Urban Water Systems, Enteric Pathogen Distribution & Gut Microbiome Development in Children: A Natural Experiment in Mozambique | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,392,100 | January 16, 2018 | December 31, 2024 | FREEMAN, MATTHEW C | reporter.nih.gov |
| Fitness of gram-negative pathogens during bacteremia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,386,158 | August 5, 2019 | July 31, 2024 | MOBLEY, HARRY L. | reporter.nih.gov |
| NK T Cell Interactions with NK Cells During Viral Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,385,657 | September 30, 2000 | April 30, 2024 | BROSSAY, LAURENT | reporter.nih.gov |
| Molecular Genetic Analysis of Mycobacterium Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,383,455 | December 1, 1988 | August 31, 2023 | JACOBS, WILLIAM ROBERT | reporter.nih.gov |
| Endothelial cell transplantation for multi-organ repair to counter radiation injury | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,380,785 | April 18, 2018 | March 31, 2025 | RAFII, SHAHIN | reporter.nih.gov |
| Discovery of novel benzimidazole resistance mechanisms | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,378,458 | July 1, 2020 | June 30, 2023 | ANDERSEN, ERIK CHRISTIAN | reporter.nih.gov |
| Development of Benzodiazepine YFV NS4B inhibitors as therapeutic agents for Yellow Fever | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,372,864 | May 1, 2018 | April 30, 2025 | CHANG, JINHONG | reporter.nih.gov |
| Discovery of Gram-negative permeable chemical probes for tRNA methylation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,368,444 | February 1, 2019 | January 31, 2025 | HOU, YA-MING | reporter.nih.gov |
| Genomic Characterization and Surveillance of Microbial Threats in West Africa | NIH | National Human Genome Research Institute | 2021 to 2022 | $1,366,854 | September 23, 2013 | June 30, 2023 | HAPPI, CHRISTIAN T. | reporter.nih.gov |
| Structure-based design of novel Lassa virus glycoproteins for vaccine development | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,352,744 | July 14, 2017 | June 30, 2023 | GARRY, ROBERT F | reporter.nih.gov |
| Dkk1-Endothelial Progenitor Cell Treatment for the Mitigation of Hematopoietic Radiation Injury | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,346,499 | March 12, 2018 | February 29, 2024 | HIMBURG, HEATHER A | reporter.nih.gov |
| Molecular and Metabolic inter-kingdom actions of a bacterial quorum sensing signal in promotion of host tolerance/resilience. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,341,908 | January 1, 2018 | December 31, 2024 | RAHME, LAURENCE G | reporter.nih.gov |
| Next-generation combination dosing strategies to combat resistant Acinetobacter baumannii | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,331,581 | November 8, 2017 | October 31, 2023 | BULITTA, JURGEN BERND | reporter.nih.gov |
| Enhancing Pathogen-specific Memory CD8+ T cell Responses in Vivo | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,328,754 | December 15, 2012 | July 31, 2024 | LAUVAU, GREGOIRE STEPHANE | reporter.nih.gov |
| Interactions between helminth colonization and the gut microbiota | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,318,066 | January 2, 2018 | December 31, 2023 | CADWELL, KEN HASHIGIWA | reporter.nih.gov |
| Estimating Cholera Burden with Cross-sectional Immunologic Data | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,310,561 | May 25, 2018 | October 31, 2023 | LEUNG, DANIEL TED | reporter.nih.gov |
| Host-Microbe Interactions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,307,013 | September 30, 1997 | July 31, 2029 | HOGAN, DEBORAH A | reporter.nih.gov |
| Rational design and evaluation of novel mRNA vaccines against MERS-CoV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,297,163 | July 1, 2021 | January 31, 2025 | DU, LANYING | reporter.nih.gov |
| Predicting tuberculosis outcomes using genotypic and biomarker signatures | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,282,364 | January 15, 2019 | June 14, 2022 | BEAMER, GILLIAN L | reporter.nih.gov |
| Previous exposure to dengue as a risk factor for Zika during pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,265,952 | January 1, 2018 | December 31, 2024 | ALIOTA, MATTHEW T | reporter.nih.gov |
| Therapy of acute radiation syndrome and its complications by mesenchymal stromal cells conditioned with Toll-like receptor 9 agonists | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,264,466 | April 1, 2018 | March 31, 2024 | LEDERER, JAMES A. | reporter.nih.gov |
| TB detection in children using a novel stool-based GeneXpert assay | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,264,372 | December 5, 2017 | November 30, 2023 | ALLAND, DAVID | reporter.nih.gov |
| Release of Extracellular DNA during Biofilm Formation in Staphylococcus aureus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,260,344 | May 11, 2018 | April 30, 2023 | LOSICK, RICHARD MARC | reporter.nih.gov |
| Novel Antibody-Oxime Pairing to Reduce Circulating Organophosphate Levels. | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $1,260,000 | May 15, 2020 | April 30, 2024 | THOMPSON, CHARLES MARK | reporter.nih.gov |
| Antiviral Lead Identification to Treat Filovirus Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,258,066 | August 12, 2019 | December 31, 2024 | DAVISSON, VINCENT JO | reporter.nih.gov |
| Mechanisms of antigen cross-presentation by MHC class I molecules | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,256,250 | June 1, 2021 | May 31, 2025 | CRESSWELL, PETER | reporter.nih.gov |
| Developmental Exposures to Arsenic: Pneumonia, Immunity, and Microbiomes (DEAPIM) | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $1,248,392 | March 10, 2021 | July 31, 2022 | PARVEZ, MUHAMMAD F | reporter.nih.gov |
| Vaccines Against Ehrlichia and Anaplasma Species Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,244,930 | June 1, 2020 | December 31, 2022 | GANTA, ROMAN R. | reporter.nih.gov |
| Fusion: Vaccine conjugate technology to advance vaccine safety and efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,244,512 | June 18, 2018 | May 31, 2025 | RYTER, KENDAL | reporter.nih.gov |
| RADIATION/NUCLEAR MEDICAL COUNTERMEASURE (MCM) PRODUCT DEVELOPMENT SUPPORT SERVICES. TASK ORDER B-1, ANIMAL MODEL DEVELOPMENT AND INITIAL EFFICACY TESTING OF CANDIDATE MCMS. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,235,113 | September 1, 2015 | August 31, 2020 | CHANG, POLLY | reporter.nih.gov |
| Impact of versican deficiency on the innate immune response to influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,232,686 | December 12, 2017 | November 30, 2023 | FREVERT, CHARLES WAYNE | reporter.nih.gov |
| Defining the functional interface between the ER and flaviviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,227,856 | June 20, 2018 | May 31, 2024 | CHERRY, SARA | reporter.nih.gov |
| Characterizing the impact of Yersinia Pestis to the phenotypic evolution of the human immune system | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $1,221,088 | September 1, 2019 | May 31, 2024 | BARREIRO, LUIS BRUNO | reporter.nih.gov |
| Technology development for point-of-care detection and antimicrobial susceptibility testing of Neisseria gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,220,681 | August 22, 2018 | July 31, 2024 | WANG, TZA-HUEI JEFF | reporter.nih.gov |
| Progenitor cell based therapy to mitigate radiation induced gastro intestinal syndrome- supplement | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,220,595 | March 7, 2018 | February 29, 2024 | SAHA, SUBHRAJIT | reporter.nih.gov |
| DEVELOPMENT OF BROAD SPECTRUM ANTIVIRALS | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,219,399 | September 27, 2011 | June 7, 2021 | DUCHARS, MATTHEW | reporter.nih.gov |
| Transcriptome and proteome remodeling by Mycobacterium tuberculosis MazF toxins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,215,943 | December 1, 2019 | November 30, 2022 | WOYCHIK, NANCY ANN | reporter.nih.gov |
| Preclinical Development of a Thermostable Trivalent Filovirus Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,211,368 | June 20, 2017 | May 31, 2023 | LEHRER, AXEL T | reporter.nih.gov |
| Genetically-encoded fluorescent RNA sensors for measuring transport of antibiotics into the cytoplasm of Gram-negative pathogens and development of efflux pump inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,209,897 | February 13, 2018 | July 31, 2023 | LORY, STEPHEN | reporter.nih.gov |
| Microbial Disruption of Dendritic Cell Maturation and Function | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,198,795 | September 24, 2018 | August 31, 2025 | GENCO, CAROLINE A | reporter.nih.gov |
| Redefining the role of autophagy in bacterial disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,194,241 | November 10, 2016 | December 31, 2022 | CADWELL, KEN HASHIGIWA | reporter.nih.gov |
| Stromal cell therapy as a treatment against Gastrointestinal Acute Radiation Syndrome (GI-ARS) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,193,484 | March 9, 2018 | February 29, 2024 | GUHA, CHANDAN | reporter.nih.gov |
| Development of Novel MetAP2 inhibitors as potential therapeutics for Microsporidiosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,192,501 | April 1, 2018 | March 31, 2024 | DAS, BHASKAR CHANDRA | reporter.nih.gov |
| Regulation of Immune Responses to Mycobacterium tuberculosis Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,188,492 | September 24, 2018 | August 31, 2024 | STALLINGS, CHRISTINA LEIGH | reporter.nih.gov |
| Innate Immunity Training Program | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,187,959 | September 15, 2011 | August 31, 2026 | SILVERMAN, NEAL | reporter.nih.gov |
| The role of non-classical MHC class I molecules in immune responses to Mycobacterium tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,184,815 | May 14, 2018 | April 30, 2025 | WANG, CHYUNG-RU | reporter.nih.gov |
| The role of hepoxilin A3 in neutrophil breach of the Infected airway mucosa. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,184,750 | February 8, 2012 | May 31, 2024 | HURLEY, BRYAN P | reporter.nih.gov |
| A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,175,961 | June 1, 2017 | May 31, 2024 | YANG, ZHIYONG | reporter.nih.gov |
| Role of skin prions in disease transmission and diagnostic testing of human prion disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $1,171,964 | September 15, 2018 | June 30, 2024 | KONG, QINGZHONG | reporter.nih.gov |
| Targeting trained immunity and Th1/Th17 axis with combination adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,167,749 | July 26, 2021 | September 1, 2022 | KHADER, SHABAANA A. | reporter.nih.gov |
| Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,166,670 | August 9, 2017 | July 31, 2024 | BARIC, RALPH S | reporter.nih.gov |
| Co-Presentation and Delivery of TLR Agonist Combinations with Subunit Antigens to Pathogen-Match the Immune Response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,165,164 | August 14, 2018 | July 31, 2024 | PUTNAM, DAVID A | reporter.nih.gov |
| A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,163,936 | March 1, 2018 | February 29, 2024 | SCHARFF, MATTHEW D | reporter.nih.gov |
| Epigenetic programming of T follicular helper cell differentiation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,163,398 | July 6, 2018 | June 30, 2024 | HALE, JEFFREY SCOTT | reporter.nih.gov |
| Function and mechanism of the mammalian RNA interference response to virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,162,633 | January 9, 2019 | December 31, 2023 | DING, SHOU-WEI | reporter.nih.gov |
| Rapid multiplex method for direct phenotypic ID/AST of bacterial pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,158,336 | May 17, 2018 | April 30, 2023 | SHARP, NATASHA JAYNA | reporter.nih.gov |
| CARD-only protein regulation of cytosolic Pattern Recognition Receptor signaling | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,157,588 | July 1, 2018 | June 30, 2024 | DORFLEUTNER, ANDREA | reporter.nih.gov |
| Development of a Universal Immunotherapeutic for Influenza Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,155,553 | March 14, 2019 | March 31, 2023 | HOLTSBERG, FREDERICK WAYNE | reporter.nih.gov |
| Investigating the role of liquid-liquid phase separation in the interaction between Mycobacterium tuberculosis and macrophages | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,152,144 | August 10, 2021 | July 31, 2026 | BELL, SAMANTHA LYNN | reporter.nih.gov |
| Comparative Analysis of Bunyavirus Neuropathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $1,149,175 | August 24, 2022 | July 31, 2024 | HARTMAN, AMY L | reporter.nih.gov |
| Identification and Characterization of Genes Required for Listeria monocytogenes Cytosolic Survival | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,147,317 | September 24, 2018 | August 31, 2024 | SAUER, JOHN-DEMIAN | reporter.nih.gov |
| Molecular Basis of Flavivirus Cross-Neutralization by Human Antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,143,274 | August 5, 2013 | August 31, 2024 | DESILVA, ARAVINDA M. | reporter.nih.gov |
| Memory, Phenotype, and Function of TB-reactive Human MR1 Restricted T cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,133,140 | February 1, 2019 | January 31, 2024 | LEWINSOHN, DAVID M. | reporter.nih.gov |
| Novel therapeutic approaches to treatment of botulinum neurotoxin poisoning. | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,132,082 | April 15, 2011 | June 30, 2022 | ICHTCHENKO, KONSTANTIN | reporter.nih.gov |
| Technical and Administrative Management Services in Support of Domestic and International Collaborative Research Efforts | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,125,216 | October 1, 2016 | July 12, 2022 | HAMRICK, SOMER | reporter.nih.gov |
| Molecular Mechanisms of Viral Entry by Membrane Fusion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,124,438 | September 1, 1991 | December 31, 2024 | TAMM, LUKAS K | reporter.nih.gov |
| Preclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktail | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,124,215 | June 26, 2017 | May 31, 2024 | GARRY, ROBERT F | reporter.nih.gov |
| Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,123,469 | August 15, 2017 | July 31, 2024 | DEGROOT, ANNE SEARLS | reporter.nih.gov |
| T cell Memory to Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,123,200 | July 1, 1990 | March 1, 2025 | AHMED, RAFI | reporter.nih.gov |
| Mechanism of radiation induced endovascular injury and mitigation via the Notch-Dll4 pathway | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,122,620 | December 11, 2017 | November 30, 2023 | HIMBURG, HEATHER A | reporter.nih.gov |
| VTEU: Phase II Clinical Trial to Evaluate Influenza Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,122,055 | July 28, 2017 | April 30, 2023 | HOFT, DANIEL | reporter.nih.gov |
| Vaccines to counter emerging antibiotic resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,121,304 | May 1, 2018 | April 30, 2023 | PICKING, WENDY L. | reporter.nih.gov |
| ORIGINS AND FUNCTIONS OF UTERINE NATURAL KILLER CELLS IN PREGNANCY | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,120,198 | August 13, 2018 | July 31, 2023 | YOKOYAMA, WAYNE M. | reporter.nih.gov |
| High throughput screening of orthosteric inhibitors of flavivirus protease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,113,417 | February 15, 2018 | January 31, 2025 | LI, HONGMIN | reporter.nih.gov |
| Staphylococcus aureus extracellular vesicles: host-pathogen interactions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,107,140 | September 1, 2019 | August 31, 2024 | WANG, XIAOGANG | reporter.nih.gov |
| Development of Paratransgenic Ticks for Disease Control | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,106,078 | July 1, 2002 | November 30, 2024 | MUNDERLOH, ULRIKE GERTRUD | reporter.nih.gov |
| Preclinical Development of Human Monoclonal Antibodies for Postexposure Treatment of Crimean-Congo Hemorrhagic Fever | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,104,705 | June 1, 2017 | May 31, 2023 | GEISBERT, THOMAS WILLIAM | reporter.nih.gov |
| Control of Influenza Infection by Lipid Mediators and Macrophages | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,099,522 | January 10, 2018 | December 31, 2024 | HAHN, YOUNG S. | reporter.nih.gov |
| Conditional Expression of Mycobacterial Genes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,094,554 | February 15, 2006 | August 31, 2024 | EHRT, SABINE | reporter.nih.gov |
| Regulation of cytosolic pattern recognition receptor signaling in macrophages | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,085,226 | March 11, 2013 | March 1, 2024 | STEHLIK, CHRISTIAN | reporter.nih.gov |
| Adenovirus manipulation of cellular chromatin to overcome host responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,084,728 | September 24, 2018 | August 31, 2024 | WEITZMAN, MATTHEW D. | reporter.nih.gov |
| A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,084,177 | July 14, 2017 | June 30, 2024 | CHANDRAN, KARTIK | reporter.nih.gov |
| Immunoregulation by indoleamine 2,3-dioxygenases in tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,083,318 | May 1, 2018 | April 30, 2024 | CHAN, JOHN R. | reporter.nih.gov |
| HLA-DO / H2-O: modulation of MHC-II peptide diversity and Treg population control | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,082,364 | December 12, 2017 | November 30, 2023 | STERN, LAWRENCE J. | reporter.nih.gov |
| Endothelial cell tropism in the pathogenesis and host response against influenza viruses - Resubmission 01 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,080,542 | December 8, 2017 | November 30, 2023 | MANICASSAMY, BALAJI | reporter.nih.gov |
| Cracking Salmonella Typhis Secret Code: Understanding Pathogenic Mechanisms of Salmonella Typhi Toxin | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,077,168 | June 4, 2018 | May 31, 2024 | SONG, JEONGMIN | reporter.nih.gov |
| New targets against tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,076,804 | July 1, 2017 | June 30, 2023 | HUNG, DEBORAH T | reporter.nih.gov |
| Characterization of a distinct NKT subset and its role in influenza responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,075,834 | May 1, 2018 | April 30, 2024 | ALBEROLA-ILA, JOSE | reporter.nih.gov |
| Chemical Methods for Ferrous Iron Dependent Drug Delivery | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,073,306 | May 29, 2013 | August 31, 2024 | RENSLO, ADAM R | reporter.nih.gov |
| Detection of asymptomatic Salmonella enterica serotype Typhi and Paratyphi A carriage by serum antibodies targeting YncE | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,072,824 | August 15, 2018 | July 31, 2024 | CHARLES, RICHELLE C | reporter.nih.gov |
| Vector and Host Contributions to the Regulation of E. Chaffeensis Gene Expression | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,072,622 | December 15, 2007 | December 31, 2022 | GANTA, ROMAN R. | reporter.nih.gov |
| Assessing measures to eliminate transmission of cholera in Haiti | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $1,072,308 | September 27, 2012 | June 30, 2025 | HARRIS, JASON B | reporter.nih.gov |
| The Functional Role of the Tetraspanin CD82/Kai1 in Fungal Innate Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,058,866 | January 11, 2018 | December 31, 2023 | VYAS, JATIN M | reporter.nih.gov |
| Mechanisms of Marburg virus gene expression | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,058,845 | May 8, 2018 | April 30, 2025 | FEARNS, RACHEL | reporter.nih.gov |
| Innate-like BCR activity as a template for universal vaccination against influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,058,052 | June 1, 2018 | May 31, 2023 | LINGWOOD, DANIEL | reporter.nih.gov |
| COVID-19 - Global Mix / Investigation of COVID-19 Disease Parameters for Transmission Models in Low-Resource Settings | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $1,055,903 | March 1, 2022 | May 31, 2023 | OMER, SAAD B. | reporter.nih.gov |
| Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,052,607 | August 18, 2017 | July 31, 2024 | BUTLER, MICHELLE M. | reporter.nih.gov |
| Regulation of IL-1β bioactivity by Cysteine S-glutathionylation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,050,304 | June 12, 2019 | April 14, 2024 | LUO, HONGBO R | reporter.nih.gov |
| Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,045,564 | June 20, 2017 | April 30, 2023 | TESTA, CHARLES | reporter.nih.gov |
| An Advanced Vaccine Candidate To Prevent Zika Virus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,043,638 | June 8, 2017 | May 31, 2023 | SLIFKA, MARK K | reporter.nih.gov |
| Radiation Mitigators Targeting Regulated Necrosis Pathways of Parthanatos Pyroptosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,043,345 | July 8, 2020 | June 30, 2025 | BAYIR, HÜLYA | reporter.nih.gov |
| High Throughput Screening for Non-antibiotic inhibitors of Clostridium difficile Pathophysiology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,041,042 | February 11, 2019 | January 31, 2024 | HURDLE, JULIAN G | reporter.nih.gov |
| Replication mechanism of human prions | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $1,036,196 | May 1, 2018 | January 31, 2024 | SAFAR, JIRI G. | reporter.nih.gov |
| Microbial Pattern Recognition and Signaling by the Adhesion GPCR BAI1 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,034,152 | November 17, 2017 | October 31, 2022 | CASANOVA, JAMES E. | reporter.nih.gov |
| Influenza D Virus Entry and Tissue Tropism | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,033,696 | September 21, 2018 | August 31, 2025 | LI, FENG | reporter.nih.gov |
| Molecular Basis of Ecdysteroid Action in the Mosquito | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,032,642 | July 1, 1995 | April 30, 2024 | RAIKHEL, ALEXANDER SIMEON | reporter.nih.gov |
| Assay development and screening for inhibitors targeting Shiga toxin 2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,031,236 | January 25, 2019 | December 31, 2024 | LI, XIAO-PING | reporter.nih.gov |
| Molecular Basis of CD1D and Natural Killer T Cell Function | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,026,763 | August 19, 2019 | July 31, 2024 | JOYCE, SEBASTIAN | reporter.nih.gov |
| Oxidative Burst in Influenza and MRSA Co-infection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,022,922 | May 22, 2013 | December 31, 2024 | SUN, KEER | reporter.nih.gov |
| The Immunogenetics of Measles Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,021,528 | September 30, 1993 | March 31, 2025 | POLAND, GREGORY A. | reporter.nih.gov |
| The Rv2623-Rv1747 interaction: regulation of the in vivo fate of M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $1,020,438 | January 16, 2020 | December 31, 2022 | CHAN, JOHN R. | reporter.nih.gov |
| The adaptor protein Crk in immune responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,012,953 | February 13, 2018 | August 20, 2023 | LIU, DONGFANG | reporter.nih.gov |
| Extending the scope of PLX-R18 for H-ARS: efficacy in special populations and DEARE | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,010,588 | March 8, 2018 | February 29, 2024 | ORSCHELL, CHRISTIE M | reporter.nih.gov |
| The Role of the Adenosine Receptor in Th Cell Development and Function | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,007,234 | December 6, 2017 | November 30, 2024 | ERNST, PETER B. | reporter.nih.gov |
| Protective and pathologic functions of macrophages induced by helminths | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,003,283 | December 20, 2017 | November 30, 2022 | SIRACUSA, MARK CHRISTOPHER | reporter.nih.gov |
| TOLLIP Deficiency, Immune Dysregulation, and Tuberculosis Susceptibility | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,003,164 | March 1, 2018 | February 29, 2024 | SHAH, JAVEED ALI | reporter.nih.gov |
| Optimization of novel pyranopyridine efflux pump inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,000,000 | March 15, 2012 | July 31, 2024 | OPPERMAN, TIMOTHY J. | reporter.nih.gov |
| Bioinformatics Tools and Services at NCBI for AMR Research | NIH | National Library of Medicine | 2022 | $1,000,000 | September 16, 2020 | September 15, 2023 | HILL, CAROLYN | reporter.nih.gov |
| Improved Influenza Vaccine Efficacy Through Infection Mimicry | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $999,900 | April 15, 2019 | January 31, 2022 | KOSUDA, KATHRYN | reporter.nih.gov |
| Influence of polysialic acid on leukocyte migration | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $999,737 | June 1, 2018 | May 31, 2024 | STAMATOS, NICHOLAS MILTON | reporter.nih.gov |
| Final Preclinical Testing and Formulation of a Scalable, Live-attenuated SARS-CoV-2 Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $999,267 | May 6, 2021 | April 30, 2023 | MUELLER, STEFFEN | reporter.nih.gov |
| Senescence-Chips for Radiation Biodosimetry | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $997,365 | August 5, 2014 | September 30, 2023 | WANG, DAOJING | reporter.nih.gov |
| Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $996,798 | August 1, 2012 | July 31, 2024 | BUTLER, MICHELLE M. | reporter.nih.gov |
| Biosynthesis and Synthetic Biology of Antibiotic Oligosaccharides | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $991,306 | June 1, 2019 | May 31, 2025 | BACHMANN, BRIAN O | reporter.nih.gov |
| Virulence Factors of Salmonella | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $991,078 | June 15, 1999 | March 31, 2024 | BAUMLER, ANDREAS J | reporter.nih.gov |
| Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $989,300 | August 18, 2017 | June 30, 2024 | LEVIN, ANDREW E. | reporter.nih.gov |
| Understanding Maternal-Fetal Zika Virus Transmission and its Complications in Nicaragua | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $988,332 | September 1, 2018 | July 31, 2025 | STRINGER, ELIZABETH MCPHILLIPS | reporter.nih.gov |
| Regulation of Ebola virus replication by the host ubiquitin system | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $987,500 | May 16, 2018 | April 30, 2024 | GIRALDO, MARIA ISABEL | reporter.nih.gov |
| Task B10: Evaluation of vaccines against VEEV and EEEV aerosol exposure in cynomolgus macaques | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $986,293 | July 14, 2017 | July 13, 2024 | JENNISKINS, TAMI | reporter.nih.gov |
| An epitope-focused nanoparticle vaccine for anthrax | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $983,698 | May 1, 2019 | May 31, 2025 | WHITACRE, DAVID C | reporter.nih.gov |
| 4-(Aminomethyl) benzamides as novel anti-Ebola agents | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $982,388 | August 7, 2016 | July 31, 2024 | RONG, LIJUN | reporter.nih.gov |
| Preclinical development of Novo29, a new antibiotic | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $977,463 | January 10, 2018 | March 31, 2023 | LING, LOSEE LUCY | reporter.nih.gov |
| MycoMEIA - Urine Diagnostic for Aspergillosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $976,576 | March 8, 2021 | February 28, 2023 | MARR, KIEREN A. | reporter.nih.gov |
| Revisiting alginate paradigms | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $976,284 | November 3, 2017 | October 31, 2023 | WOZNIAK, DANIEL J | reporter.nih.gov |
| Role of Transcription Coactivator OCA-B in Gene Poising and Immunological Memory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $973,062 | December 1, 2012 | December 31, 2023 | TANTIN, DEAN | reporter.nih.gov |
| Non-redundant functions of type 3 innate lymphoid cells in mucosal immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $966,074 | April 1, 2019 | March 31, 2025 | IVANOV, IVAYLO IVANOV | reporter.nih.gov |
| TCR-dependent activation, functional differentiation and memory formation of CD4+ T cells following infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $965,376 | January 17, 2018 | December 31, 2023 | WILLIAMS, MATTHEW A | reporter.nih.gov |
| Survival of Neisseria gonorrhoeae after primary human neutrophil challenge | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $961,942 | July 1, 2012 | October 31, 2024 | CRISS, ALISON K | reporter.nih.gov |
| Translation Regulation by Enterovirus Proteinase | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $960,000 | March 1, 2002 | July 31, 2024 | LLOYD, RICHARD E | reporter.nih.gov |
| Mechanisms of intracellular pathogen dissemination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $956,974 | June 1, 2007 | April 30, 2024 | AGAISSE, HERVE F | reporter.nih.gov |
| Optimization of novel thioesters as a therapeutic strategy for combating opioid overdoses and abuse | NIH | National Institute on Drug Abuse | 2021 to 2022 | $956,514 | September 1, 2020 | July 31, 2023 | LEWIS, STEPHEN JOHN | reporter.nih.gov |
| The developmental layers in the CD8+ T cell response to chronic infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $956,026 | March 1, 2014 | July 31, 2024 | RUDD, BRIAN DAVID | reporter.nih.gov |
| Mechanisms of DDO Adjuvancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $944,185 | August 15, 2018 | July 31, 2024 | LOPEZ, CAROLINA B. | reporter.nih.gov |
| The LiaFSR system and antimicrobial peptide resistance in enterococci | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $943,570 | May 18, 2018 | June 30, 2024 | ARIAS, CESAR AUGUSTO | reporter.nih.gov |
| Characterizing the strain and host range properties of prions causing emergent forms of chronic wasting disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $938,092 | September 30, 2018 | June 30, 2024 | TELLING, GLENN C | reporter.nih.gov |
| Anti-inflammatory functions for non-transcriptional IRF3 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $935,898 | February 8, 2021 | January 31, 2024 | CHATTOPADHYAY, SAURABH | reporter.nih.gov |
| Molecular mechanisms of eastern equine encephalitis virus pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $934,796 | February 1, 2012 | May 31, 2024 | KLIMSTRA, WILLIAM B | reporter.nih.gov |
| Protective CD4+ T Cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $934,776 | March 15, 2013 | February 29, 2024 | JENKINS, MARC KEVIN | reporter.nih.gov |
| Natural killer cell cytotoxicity against intracellular bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $933,720 | May 1, 2020 | February 28, 2023 | MIAO, EDWARD A | reporter.nih.gov |
| Costimulatory Signals in CD4+ T Cell Activation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $933,240 | April 1, 1989 | March 31, 2024 | JENKINS, MARC KEVIN | reporter.nih.gov |
| INFLUENZA-SPECIFIC IMMUNITY AND RESPONSES TO INACTIVATED INFLUENZA VACCINE IN INFANTS: EFFECT OF MATERNAL VACCINATION DURING PREGNANCY | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $932,996 | June 18, 2020 | May 31, 2025 | WEINBERG, ADRIANA | reporter.nih.gov |
| Mechanisms of prion spread and establishment of infection | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $931,420 | June 15, 2018 | April 30, 2024 | BARTZ, JASON C | reporter.nih.gov |
| A Mechanism Based Approach to Metallo beta-lactamase Inhibition | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $930,704 | February 7, 2012 | May 31, 2024 | BONOMO, ROBERT A. | reporter.nih.gov |
| The role of Esx-3 in mediating drug resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $929,996 | January 1, 2020 | August 31, 2024 | PARISH, TANYA | reporter.nih.gov |
| An immunotherapeutic to prevent gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $928,633 | August 1, 2019 | July 31, 2023 | WYCOFF, KEITH | reporter.nih.gov |
| Mapping Drug Resistance Genes in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $923,047 | September 1, 2000 | November 30, 2022 | ANDERSON, TIM J | reporter.nih.gov |
| Regulation of IL10 production in CD8+ T cells during Flu infection by tyrosine kinase Itk | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $921,550 | June 18, 2018 | May 31, 2024 | AUGUST, AVERY | reporter.nih.gov |
| Discovery and validation of broadly effective LpxH inhibitors as novel therapeutics against multi-drug resistant Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $916,560 | February 1, 2019 | January 31, 2023 | ZHOU, PEI | reporter.nih.gov |
| Modeling immunity with a hybrid lymph node tissue-chip | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $915,562 | December 20, 2017 | November 30, 2023 | POMPANO, REBECCA R | reporter.nih.gov |
| The Role of Canonical and Non-canonical Autophagy in B Cell Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $915,469 | March 1, 2018 | February 29, 2024 | BATISTA, FACUNDO DAMIAN | reporter.nih.gov |
| Phenotypic, Functional and Transcriptional Heterogeneity in T Cell Exhaustion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $914,926 | December 16, 2019 | August 26, 2022 | CUI, WEIGUO | reporter.nih.gov |
| Digital High Resolution Melt and Machine Learning for Rapid and Specific Diagnosis in Neonatal Sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $910,568 | May 1, 2018 | April 30, 2023 | FRALEY, STEPHANIE IRENE | reporter.nih.gov |
| Translational Regulation of CD8 T-Cell Immunity - Transfer of R01AI139675 from Emory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $909,274 | August 14, 2018 | July 31, 2024 | ARAKI, KOICHI | reporter.nih.gov |
| The Rv2623-Rv1747 interaction: regulation of the in vivo fate of M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $908,865 | January 16, 2020 | September 15, 2021 | CHAN, JOHN R. | reporter.nih.gov |
| Transmission and Pathogenesis of Chronic Wasting Disease (CWD) | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $906,631 | September 30, 2009 | February 29, 2024 | MATHIASON, CANDACE K. | reporter.nih.gov |
| Central metabolism of Salmonella in the inflamed gut | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $904,111 | February 24, 2021 | June 30, 2022 | WINTER, SEBASTIAN E | reporter.nih.gov |
| Mechanisms of age-specific differences in the Type I IFN response to respiratory viral infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $901,284 | September 8, 2020 | August 31, 2024 | CAREY, ALISON J | reporter.nih.gov |
| CD4 T cell, germinal center, and antibody response defects in recurrent tonsillitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $900,000 | June 14, 2018 | May 31, 2024 | CROTTY, SHANE P | reporter.nih.gov |
| Role of proteasome activity in adaptive immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $898,114 | December 1, 2017 | November 30, 2023 | CHANG, JOHN T | reporter.nih.gov |
| Pharmacokinetics and Immunodynamics of Immune stimulating chemotherapeuticnanoparticles for TB | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $897,200 | August 15, 2018 | July 31, 2024 | REYNOLDS, JESSICA L | reporter.nih.gov |
| Metabolic Network Remodeling in Epstein-Barr Virus Lymphomagenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $895,000 | March 15, 2018 | February 28, 2023 | GEWURZ, BENJAMIN ELISON | reporter.nih.gov |
| Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $894,983 | September 30, 2020 | August 31, 2024 | REDDY, DOODIPALA SAMBA | reporter.nih.gov |
| Age-dependent role of type I interferon in Bordetella pertussis pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $893,462 | September 19, 2018 | August 31, 2024 | CARBONETTI, NICHOLAS H | reporter.nih.gov |
| A Neonatal Monkey Model of Tuberculosis Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $893,080 | June 1, 2019 | May 31, 2023 | JAGANNATH, CHINNASWAMY | reporter.nih.gov |
| Antidotes against HCI-induced chronic lung injury | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $892,843 | August 20, 2020 | August 31, 2024 | CATRAVAS, JOHN D | reporter.nih.gov |
| Structure, function and engineering of immune cytokine receptor signaling | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $888,735 | April 1, 2002 | June 30, 2023 | GARCIA, KENAN CHRISTOPHER | reporter.nih.gov |
| Rationally Designed Pan-Ebolavirus Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $886,705 | June 20, 2017 | January 24, 2023 | AMAN, M JAVAD | reporter.nih.gov |
| Predictive Modeling of Influenza-Pneumococcal Coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $885,870 | July 1, 2018 | June 30, 2024 | SMITH, AMBER M | reporter.nih.gov |
| Nuclear Receptor Control of T Cell Function in Discrete Intestinal Microenvironments | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $885,846 | September 23, 2021 | September 2, 2022 | SUNDRUD, MARK SCOTT | reporter.nih.gov |
| Analysis of a novel peptidoglycan assembly pathway in mycobacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $882,932 | July 1, 2018 | June 30, 2024 | PAVELKA, MARTIN S. | reporter.nih.gov |
| The Role of the RIP Kinases in Coordinating Neuroinflammation and Host Defense | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $882,500 | February 1, 2018 | January 31, 2023 | OBERST, ANDREW ATWELL | reporter.nih.gov |
| A multivalent, easy-to-use product to mitigate and treat radiation exposure | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $877,876 | January 1, 2019 | April 30, 2023 | YEN, RICHARD | reporter.nih.gov |
| Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $876,712 | April 6, 2015 | July 31, 2023 | CLEMENTS, DAVID E | reporter.nih.gov |
| Nuclear Receptor Control of T Cell Function in Discrete Intestinal Microenvironments | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $874,967 | September 23, 2021 | April 1, 2022 | SUNDRUD, MARK SCOTT | reporter.nih.gov |
| Roles of the Nucleoprotein 3'-5' Exonuclease Domain in Arenavirus Biology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $868,750 | April 1, 2019 | March 31, 2024 | DE LA TORRE, JUAN C. | reporter.nih.gov |
| Mechanisms of phenotypic antibiotic resistance in Gram-negative bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $868,325 | September 24, 2018 | August 31, 2023 | WEISS, DAVID S | reporter.nih.gov |
| Microbiome-host interplay in viral respiratory infections: A tracheostomy cohort | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $863,496 | August 11, 2021 | July 31, 2023 | MANSBACH, JONATHAN M | reporter.nih.gov |
| Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $862,755 | July 11, 2017 | June 30, 2024 | RAM, SANJAY | reporter.nih.gov |
| Early life B cell responses and inflammation following SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $854,272 | September 17, 2021 | June 30, 2022 | FOUDA AMOU OU, GENEVIEVE GINY | reporter.nih.gov |
| Coxiella manipulation of cholesterol in the intracellular niche | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $853,119 | May 1, 2018 | April 30, 2024 | GILK, STACEY D | reporter.nih.gov |
| DNA repair pathway choice and significance in targeted genome editing of Aedes aegypti | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $850,840 | January 3, 2018 | December 31, 2023 | ADELMAN, ZACH N. | reporter.nih.gov |
| Harnessing ZBP1-driven cell death to improve influenza vaccine efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $847,917 | August 13, 2021 | July 31, 2023 | BALACHANDRAN, SIDDHARTH | reporter.nih.gov |
| Regulation and function of innate lymphoid cells in the gut | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $847,500 | August 15, 2011 | February 29, 2024 | ARTIS, DAVID | reporter.nih.gov |
| New requirements for immunity to parasitic pathogens - when vaccines work and why they fail | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $846,122 | September 24, 2018 | August 31, 2024 | JENSEN, KIRK DAVID CHRISTIAN | reporter.nih.gov |
| Predictive Approaches and Technology Development for Identification of Susceptibility to Multiple Independent Infections in Trauma Patients | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $844,817 | August 24, 2021 | July 31, 2024 | RAHME, LAURENCE G | reporter.nih.gov |
| Development of the Next Generation of Conjugate Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $843,503 | July 25, 2018 | June 30, 2023 | TEYTON, LUC | reporter.nih.gov |
| ROLE OF ESXG-ESXH IN MYCOBACTERIUM TUBERCULOSIS PATHOGENESIS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $843,436 | July 1, 2011 | December 31, 2023 | PHILIPS, JENNIFER A | reporter.nih.gov |
| A Comprehensive approach to bacterial osmotolerance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $840,632 | June 11, 2018 | May 31, 2025 | SUKHAREV, SERGEI I | reporter.nih.gov |
| Targeting the Urgent Need for New Antibiotics against Gram-negative ‘Superbugs’ | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $840,469 | August 1, 2017 | July 31, 2023 | LI, JIAN | reporter.nih.gov |
| Pathogenesis of Pf Bacteriophages in Pseudomonas Cystic Fibrosis lung Infections | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $838,918 | August 1, 2019 | July 31, 2024 | MILLA, CARLOS | reporter.nih.gov |
| Pathogenesis of Borrelia miyamotoi infection and Lyme coinfection in mice | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $837,500 | December 1, 2017 | November 30, 2022 | BOCKENSTEDT, LINDA K. | reporter.nih.gov |
| The role of NLRP6 and DHX15 in control of infection by RNA viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $837,500 | January 1, 2018 | December 31, 2023 | FIKRIG, EROL | reporter.nih.gov |
| Composition and formation of the cyst wall | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $835,000 | June 1, 2018 | May 31, 2024 | WEISS, LOUIS M. | reporter.nih.gov |
| Mechanisms of viral RNA maturation by co-opting cellular exonucleases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $833,933 | June 1, 2022 | April 30, 2023 | KIEFT, JEFFREY S | reporter.nih.gov |
| TAM Receptors and Virus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $833,577 | August 21, 2012 | April 30, 2022 | LEMKE, GREG E | reporter.nih.gov |
| COMPUTATIONAL TOOLS FOR THE ANALYSIS OF HIGH-THROUGHPUT IMMUNOGLOBULIN SEQUENCING EXPERIMENTS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $832,277 | April 15, 2014 | December 31, 2024 | KLEINSTEIN, STEVEN H. | reporter.nih.gov |
| Phase variation of virulence factors in Clostridium difficile | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $830,984 | May 20, 2013 | August 31, 2024 | TAMAYO, RITA | reporter.nih.gov |
| Validation of Biomarkers of Pediatric TB and further development for use in diagnosis of childhood TB | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $830,713 | December 15, 2016 | November 30, 2022 | LEVIN, MICHAEL | reporter.nih.gov |
| Mycobacterial trehalose metabolism as drug targets | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $827,395 | July 1, 2018 | June 30, 2025 | RONNING, DONALD R | reporter.nih.gov |
| Integrated point-of-care diagnostic and data reporting platform for emerging arboviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $827,010 | August 10, 2019 | April 30, 2022 | HERRERA, BOBBY BROOKE | reporter.nih.gov |
| A Preclinical Program for Targeting Mycobacterium tuberculosis KasA | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $826,401 | August 10, 2021 | July 31, 2022 | FREUNDLICH, JOEL STEPHEN | reporter.nih.gov |
| Revolutionary Eilat-based Chikungunya Vaccine Vector | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $825,842 | June 1, 2017 | November 30, 2023 | WANG, TIAN | reporter.nih.gov |
| Biology and infection of bats with novel bat influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $824,854 | January 10, 2018 | December 31, 2024 | MA, WENJUN | reporter.nih.gov |
| The role of UBXNs in antiviral immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $821,750 | January 1, 2019 | December 31, 2022 | WANG, PENGHUA | reporter.nih.gov |
| Novel adjuvant to boost humoral and cellular immune responses against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $820,609 | May 15, 2018 | April 30, 2025 | CHEN, XINYUAN | reporter.nih.gov |
| Plasmid-Bacteria Coevolution Promotes the Spread of Antibiotic Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $819,960 | May 1, 2010 | April 30, 2025 | TOP, EVA M. | reporter.nih.gov |
| Neutral lipid metabolism during Toxoplasma infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $818,750 | May 4, 2018 | April 30, 2024 | COPPENS, ISABELLE | reporter.nih.gov |
| Cytoskeletal machinery driving invasion by the human pathogen, Toxoplasma gondii. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $817,254 | January 1, 2018 | December 31, 2023 | HU, KE | reporter.nih.gov |
| Nutritional regulation of pathogenesis in Staphylococcus aureus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $815,616 | July 3, 2018 | August 7, 2024 | BRINSMADE, SHAUN R | reporter.nih.gov |
| Preclinical development of an immunomodulatory agent capable of mitigating influenza related hypercytokinemia | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $813,514 | May 8, 2020 | April 30, 2023 | CRAIGO, JODI K | reporter.nih.gov |
| Discovery of Hsp100-selective inhibitors for targeting multiple microbial pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $807,855 | July 1, 2019 | June 30, 2025 | ZOLKIEWSKI, MICHAL | reporter.nih.gov |
| Impact of prior influenza exposures on antibody repertoires to new viral strains | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $807,244 | August 15, 2014 | July 31, 2024 | HENSLEY, SCOTT ERIC | reporter.nih.gov |
| Altered innate leukocyte programming dynamics in sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $805,000 | November 15, 2017 | October 31, 2023 | LI, LIWU | reporter.nih.gov |
| STATISTICAL AND DATA COORDINATING CENTER FOR CLINICAL RESEARCH ON INFECTIOUS DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $802,360 | March 1, 2015 | February 28, 2021 | EWELL, MARIAN | reporter.nih.gov |
| Bacterial modulation of noncanonical inflammasome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $797,500 | January 16, 2018 | September 7, 2023 | KAILASAN VANAJA, SIVAPRIYA | reporter.nih.gov |
| Smartphone-linked system for diagnosis and epidemiological reporting of pathogens at the point of care | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $796,842 | September 5, 2019 | August 31, 2025 | CUNNINGHAM, BRIAN T. | reporter.nih.gov |
| Regulation of inflammatory gene expression during SARS2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $794,868 | February 18, 2022 | October 3, 2022 | MARAZZI, IVAN | reporter.nih.gov |
| IND-enabling studies of the potent LpxC inhibitor LPC-233 as a novel antibiotic against Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $794,342 | April 16, 2020 | September 30, 2022 | DUNCAN, CLAYTON | reporter.nih.gov |
| Nutrient Uptake during Anthrax Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $792,500 | June 21, 2012 | October 31, 2023 | MARESSO, ANTHONY W | reporter.nih.gov |
| Diet driven evolution of epidemic ribotypes of Clostridium difficile | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $792,500 | November 17, 2017 | October 31, 2023 | BRITTON, ROBERT A | reporter.nih.gov |
| Multipurpose targeted nano-antibiotic therapy to fight tough infection in bones | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $792,500 | September 20, 2018 | August 31, 2024 | WONG, HO-LUN | reporter.nih.gov |
| IgM in the regulation of TB immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $792,158 | December 1, 2021 | January 31, 2023 | CHAN, JOHN R. | reporter.nih.gov |
| The Mechanism of Cytoplasmic Incompatibility | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $791,875 | January 1, 2020 | July 31, 2022 | BORDENSTEIN, SETH R | reporter.nih.gov |
| Mechanisms and Circumvention of Daptomycin Resistance in Streptococcus mitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $791,490 | November 15, 2017 | October 31, 2023 | BAYER, ARNOLD S | reporter.nih.gov |
| Mechanism of the short- and long-term effects of COVID-19-induced Alarmins on hematopoietic stem and progenitor cells. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $790,250 | September 1, 2021 | June 30, 2023 | LIANG, YING | reporter.nih.gov |
| High Throughput Screening of Inhibitors Targeting the Enterovirus A71 and D68 2A proteases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $790,161 | June 17, 2019 | May 31, 2024 | WANG, JUN | reporter.nih.gov |
| Post-exposure immunotherapy for ricin exposure | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $788,841 | June 29, 2018 | December 31, 2024 | BRENNAN, MILES BURKE | reporter.nih.gov |
| Molecular Mechanism of Action of the Influenza PA-X Host Shutoff Protein | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $788,424 | May 25, 2018 | April 30, 2024 | GAGLIA, MARTA MARIA | reporter.nih.gov |
| Molecular Mechanisms of Protein Sorting by the Type II Secretion System | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $787,784 | September 24, 2018 | August 31, 2024 | SANDKVIST, MARIA B | reporter.nih.gov |
| DEFINING NOVEL, EVOLUTIONARILY CONSERVED HOST FACTORS CRITICAL FOR VIRUS INFECTION. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $787,500 | May 2, 2018 | April 30, 2024 | WANG, DAVID | reporter.nih.gov |
| Mechanisms of Diet-Induced Pathogen Expansion in the Gut | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $785,744 | June 1, 2018 | May 31, 2023 | MONACK, DENISE M | reporter.nih.gov |
| VENOUS: A translational study of enterococcal bacteremia | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $785,566 | June 17, 2020 | May 31, 2022 | ARIAS, CESAR AUGUSTO | reporter.nih.gov |
| Typhoid Vaccines Targeting Both Salmonella Typhi and Its Secreted Virulence Factor | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $785,000 | June 8, 2018 | May 31, 2024 | SONG, JEONGMIN | reporter.nih.gov |
| Interactions of tick-borne pathogens, Borrelia burgdorferi and Babesia microti with the mammalian host using rodent model of co-infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $785,000 | August 9, 2019 | July 31, 2025 | PARVEEN, NIKHAT | reporter.nih.gov |
| LincRNAs in Mucosal Defense to AIDS Opportunistic Pathogen Cryptosporidium | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $785,000 | November 6, 2017 | October 31, 2024 | CHEN, XIAN-MING | reporter.nih.gov |
| Advanced TRPA1 Inhibitor for the Treatment of Chlorine Inhalation Injury | NIH | National Institute of Environmental Health Sciences | 2021 | $784,984 | September 1, 2019 | August 31, 2024 | JORDT, SVEN-ERIC | reporter.nih.gov |
| Cohort and biomarkers for COVID-19 severity, natural history, and reinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $784,970 | September 17, 2021 | August 31, 2022 | BLASER, MARTIN J | reporter.nih.gov |
| Prospectively characterizing the functional and antigenic effects of mutations to viral entry proteins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $783,041 | September 24, 2018 | August 31, 2025 | BLOOM, JESSE D | reporter.nih.gov |
| Training in Immunology and Microbiology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $781,044 | September 30, 1989 | June 30, 2025 | STERN, LAWRENCE J. | reporter.nih.gov |
| Human B cell responses to a live attenuated cholera vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $780,000 | July 1, 2018 | June 30, 2025 | WRAMMERT, JENS PETER | reporter.nih.gov |
| Membrane trafficking in innate immunity to bacterial pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $780,000 | September 14, 2018 | August 31, 2024 | MANTEGAZZA, ADRIANA RITA | reporter.nih.gov |
| Obesity associated viral pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $777,500 | September 14, 2018 | August 31, 2023 | WHITMIRE, JASON KYLE | reporter.nih.gov |
| Antibody-based countermeasures against fentanyl and its analogues | NIH | National Institute on Drug Abuse | 2021 | $775,120 | September 1, 2020 | December 31, 2021 | PRAVETONI, MARCO | reporter.nih.gov |
| Antibody-based countermeasures against fentanyl and its analogues | NIH | National Institute on Drug Abuse | 2022 | $774,408 | August 1, 2022 | July 31, 2024 | PRAVETONI, MARCO | reporter.nih.gov |
| Mechanisms of Protection of Universal Therapeutic Antibodies to Influenza A | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $773,720 | January 1, 2019 | December 31, 2023 | PAUST, SILKE | reporter.nih.gov |
| B cell population structure in mouse and man | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $773,460 | August 21, 2019 | July 31, 2024 | SINGH, HARINDER | reporter.nih.gov |
| Translation of novel and repurposed drugs to address the acute and late effects of mustard exposure | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $773,440 | August 1, 2018 | July 31, 2024 | LU, KURT | reporter.nih.gov |
| Unfolded protein response in Influenza virus infection and inflammation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $772,859 | January 15, 2019 | December 31, 2023 | ANATHY, VIKAS | reporter.nih.gov |
| Enterovirus manipulation of autophagic trafficking pathways | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $772,500 | August 7, 2019 | July 31, 2023 | JACKSON, WILLIAM T | reporter.nih.gov |
| Mechanisms regulating vimentin-dependent invasion of the brain by Listeria monocytogenes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $770,626 | July 26, 2019 | December 31, 2023 | HIGGINS, DARREN E | reporter.nih.gov |
| Innate Immune Mechanisms at the Maternal-Fetal Interface in Normal and Superovulatory Pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $770,564 | August 21, 2019 | July 31, 2022 | DOUGLAS, NATAKI C | reporter.nih.gov |
| Tryptophan derivatives in EHEC pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $770,263 | February 1, 2021 | August 7, 2022 | SPERANDIO, VANESSA | reporter.nih.gov |
| The effects of influenza virus genomic heterogeneity on replication dynamics and the host response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $770,146 | September 21, 2018 | August 31, 2024 | BROOKE, CHRISTOPHER BYRON | reporter.nih.gov |
| Antibiotic activities against S. aureus during P. aeruginosa co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $769,472 | January 1, 2018 | December 31, 2022 | CONLON, BRIAN PATRICK | reporter.nih.gov |
| Development of multivalent, ultrapotent nanobody cocktails for SARS-CoV-2 neutralization | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $769,010 | February 9, 2022 | February 18, 2022 | SHI, YI | reporter.nih.gov |
| Role and Mitigation of Inflammasomes and Inflammation During COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $768,215 | September 1, 2021 | June 30, 2022 | TING, JENNY P | reporter.nih.gov |
| Optimization of antimalarials targeting multiple life stages of the parasite | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $768,193 | August 4, 2021 | July 31, 2026 | CARLIER, PAUL R | reporter.nih.gov |
| How Do Arboviruses Escape the Mosquito Midgut?- Analysis of a Novel Mechanism | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $765,536 | November 3, 2017 | October 31, 2024 | FRANZ, ALEXANDER W E | reporter.nih.gov |
| Mechanisms of iNKT cell anti-viral adjuvancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $765,000 | August 7, 2018 | July 31, 2025 | GUMPERZ, JENNY E. | reporter.nih.gov |
| Genome exploration through toxin-mediated ribosome stalling | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $763,684 | May 7, 2020 | April 30, 2023 | WOYCHIK, NANCY ANN | reporter.nih.gov |
| Innate modulation of autoimmune, regulatory, and effector B cells in adipose tissue | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $762,500 | November 23, 2017 | January 31, 2023 | LEADBETTER, ELIZABETH ANN | reporter.nih.gov |
| Exploiting synergistic and antagonistic interactions with antifungal drugs to improve disease treatment. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $762,500 | August 8, 2019 | July 31, 2024 | BROWN, JESSICA CONRAD | reporter.nih.gov |
| SET Domain Epigenetic Factors Govern Antifungal Drug Efficacy and Fungal Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $760,492 | September 24, 2018 | August 31, 2025 | BRIGGS, SCOTT D | reporter.nih.gov |
| Rocky Mountain Spotted Fever Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $760,029 | September 1, 2021 | December 31, 2022 | GANTA, ROMAN R. | reporter.nih.gov |
| Advanced Development of Drugs to Mitigate Parathion Intoxication | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $759,216 | September 30, 2018 | September 29, 2022 | LASKIN, JEFFREY D | reporter.nih.gov |
| Integrated Multi-omics of Melioidosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $758,287 | August 23, 2018 | July 31, 2023 | WEST, TIMOTHY EOIN | reporter.nih.gov |
| Enriching SARS-CoV-2 sequence data in public repositories with information extracted from full text articles | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $757,140 | September 17, 2021 | August 31, 2022 | GONZALEZ HERNANDEZ, GRACIELA | reporter.nih.gov |
| Modeling Filovirus Infection of and Trafficking through Skin | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $756,964 | August 1, 2018 | July 31, 2023 | MAURY, WENDY JEAN | reporter.nih.gov |
| Development of a multivalent vaccine against Coccidioides infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $756,656 | May 8, 2018 | April 30, 2025 | HUNG, CHIUNG-YU | reporter.nih.gov |
| The role of Bik in the replication and severity of influenza A virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $754,629 | January 1, 2021 | August 8, 2022 | MEBRATU, YOHANNES AFEWORK | reporter.nih.gov |
| A Novel Point-of-Care Assay for Diagnosing TB from Blood using Exosomes | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $754,249 | May 1, 2022 | April 30, 2025 | RODWELL, TIMOTHY CHARLES | reporter.nih.gov |
| Mechanisms of cellular respiration-dependent cell lysis and its impact on biofilm formation and disassembly in Staphylococcus aureus. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $753,550 | June 1, 2018 | May 31, 2025 | BOYD, JEFF M | reporter.nih.gov |
| Regulation of T cell immunity to viral infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $753,300 | December 15, 2007 | June 30, 2024 | GOLDRATH, ANANDA W | reporter.nih.gov |
| The role of arginine catabolic pathways in modulating staphylococcal fitness | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $752,500 | November 6, 2017 | October 31, 2023 | THOMAS, VINAI | reporter.nih.gov |
| Mechanism of Flavivirus RNA Capping | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $749,986 | January 1, 2018 | December 31, 2023 | GEISS, BRIAN | reporter.nih.gov |
| Development of Human Anthrax Immune Globulin | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $749,260 | September 28, 2007 | December 31, 2011 | ROBERT, HOPKINS | reporter.nih.gov |
| Regulation of Staphylococcus aureus colonization and disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $748,972 | September 1, 2019 | August 31, 2024 | HORSWILL, ALEXANDER R | reporter.nih.gov |
| Oral Protein Therapeutics Against C. difficile Associated Colitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $747,660 | September 1, 2021 | August 31, 2023 | CHEN, ZHILEI | reporter.nih.gov |
| Advanced Development of Drugs to Mitigate Parathion Intoxication | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $747,420 | September 30, 2018 | August 31, 2025 | LASKIN, JEFFREY D | reporter.nih.gov |
| Mechanisms of prion strain dynamics | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $746,985 | September 30, 2018 | June 30, 2024 | BARTZ, JASON C | reporter.nih.gov |
| PTPN22 R619W in NOD mice | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $745,163 | June 1, 2017 | May 31, 2022 | SHERMAN, LINDA A | reporter.nih.gov |
| Strain Dependent Structure and Function of the Influenza NS1 Protein | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $742,500 | November 16, 2017 | October 31, 2024 | PETIT, CHAD | reporter.nih.gov |
| The Roles of LPS-Binding Protein Vascular Peroxidase-1 in Innate Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $742,500 | January 4, 2019 | December 31, 2023 | CHENG, GUANGJIE | reporter.nih.gov |
| Understanding measles vaccine failure (and success) in Southern India | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $742,443 | March 1, 2017 | February 29, 2024 | KENNEDY, RICHARD B | reporter.nih.gov |
| Novel Defensins in Human Epithelial Tissues | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $741,775 | July 1, 1993 | January 31, 2024 | BEVINS, CHARLES L | reporter.nih.gov |
| Combining Aedes aegypti genomics and modeling to improve gene drive strategies and our understanding of resistance evolution | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $740,683 | June 5, 2018 | May 31, 2024 | GOULD, FRED | reporter.nih.gov |
| Development of a novel vaccine platform: Surface Antigen/Adjuvant Vaccine Engineering (SAAVE) | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $740,465 | May 22, 2017 | April 30, 2023 | TRENT, MICHAEL STEPHEN | reporter.nih.gov |
| DEFINING THE ROLE OF CELL MIGRATION IN HUMAN NK CELL DIFFERENTIATION | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $739,666 | July 2, 2018 | June 30, 2023 | MACE, EMILY MARGARET | reporter.nih.gov |
| IL-1β regulation of Zika-mediated adverse perinatal outcomes | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $735,432 | September 21, 2018 | October 3, 2022 | BURD, IRINA | reporter.nih.gov |
| Evolution of anti-filovirus B cell responses and mechanisms of protection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $733,183 | April 1, 2017 | March 31, 2023 | AMAN, M JAVAD | reporter.nih.gov |
| The "Disaggregase" Mechanism of Holotoxin Disassembly by Protein Disulfide Isomerase | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $730,991 | February 3, 2018 | January 31, 2024 | TETER, KENNETH R | reporter.nih.gov |
| The Missing Millions: Identification and infectiousness of undiagnosed tuberculosis cases in the community (the MI-TB study) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $730,577 | August 22, 2019 | July 31, 2024 | DHEDA, KEERTAN UNKHA | reporter.nih.gov |
| Mechanism of Lassa fever virus Z protein in immune suppression and viral virulence | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $730,564 | March 8, 2017 | February 28, 2024 | LIANG, YUYING | reporter.nih.gov |
| Advancing ribosome-targeting antibacterial peptides with a unique mechanism of action | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $730,027 | July 16, 2021 | February 7, 2022 | MANKIN, ALEXANDER S | reporter.nih.gov |
| Structure-Based Design of a Broadly Protective Group A Streptococcal Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $729,285 | June 8, 2017 | December 31, 2023 | DALE, JAMES B. | reporter.nih.gov |
| DETERMINING THE ROLE OF THE REPLICATIVE HELICASE IN HUMAN NK CELL DEVELOPMENT | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $729,000 | September 24, 2018 | August 31, 2023 | MACE, EMILY MARGARET | reporter.nih.gov |
| Biology of α-linked glycosylceramides in the immune system | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $723,259 | January 2, 2017 | December 31, 2022 | TEYTON, LUC | reporter.nih.gov |
| Mechanisms of PbgA involvement in Salmonella Typhimurium lipid homeostasis for bacterial pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $721,400 | May 1, 2018 | April 30, 2024 | DALEBROUX, ZACHARY DAVID | reporter.nih.gov |
| Cell Envelope Biogenesis in Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $717,750 | September 14, 2018 | August 31, 2024 | SEELIGER, JESSICA CHUANG | reporter.nih.gov |
| Antimicrobial resistant E. coli before and after California Senate bill 27 (ARES): a natural experiment | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $716,971 | May 9, 2017 | April 30, 2023 | TARTOF, SARA | reporter.nih.gov |
| Spatio-temporal data integration methods for infectious disease surveillance | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $716,058 | February 1, 2017 | January 31, 2023 | REMAIS, JUSTIN V | reporter.nih.gov |
| Biosynthetic studies and development of ribomimetic-based anti-infectives | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $715,481 | January 8, 2018 | December 31, 2023 | MAHMUD, TAIFO | reporter.nih.gov |
| Experimental evolution of Wolbachia-mediated dengue virus blocking in the mosquito, Aedes aegypti | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $714,773 | March 5, 2019 | February 29, 2024 | MCGRAW, ELIZABETH ANN | reporter.nih.gov |
| Development of a new class of antifungals effective against Cryptococcus | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $714,554 | February 12, 2019 | January 31, 2023 | SHARP, MARC | reporter.nih.gov |
| Cholera persistence, transmission, and clinical illness in Haiti | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $712,682 | December 2, 2016 | November 30, 2023 | MORRIS, JOHN GLENN | reporter.nih.gov |
| Inhibition of viral entry by interferon-induced proteins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $711,918 | July 1, 2018 | June 30, 2024 | MELIKIAN, GREGORY B | reporter.nih.gov |
| Molecular basis of action and pathogenesis of Clostridium difficile toxin B | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $705,203 | June 1, 2017 | May 31, 2023 | DONG, MIN | reporter.nih.gov |
| Effects of aging on primary and secondary vaccine responses in a 15-year longitudinal cohort | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $704,782 | April 1, 2017 | March 31, 2024 | BOYD, SCOTT DEXTER | reporter.nih.gov |
| Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $702,876 | August 1, 2014 | February 28, 2023 | AMAN, M JAVAD | reporter.nih.gov |
| Role of CD300 Family in Norovirus Tropism, Persistence, and Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $699,874 | May 22, 2017 | April 30, 2023 | BALDRIDGE, MEGAN T | reporter.nih.gov |
| Biosynthesis of Marine Polyketide Antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $697,500 | August 1, 2000 | December 31, 2023 | MOORE, BRADLEY S | reporter.nih.gov |
| Characterization of Rifabutin Therapy Against Antibiotic-Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $696,618 | August 10, 2018 | July 31, 2023 | LUNA, BRIAN MICHAEL | reporter.nih.gov |
| Novel Genetic Mechanism of Artemisinin Resistance for Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $694,949 | April 5, 2013 | June 30, 2023 | WIRTH, DYANN F | reporter.nih.gov |
| STRUCTURE-GUIDED RECEPTOR/INHIBITOR TRIMERIZATION AND RELATED STRATEGIES AGAINST CORONAVIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $686,255 | August 17, 2022 | July 31, 2024 | KE, AILONG | reporter.nih.gov |
| T cell modulation of COVID-19 disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $686,250 | September 20, 2021 | August 31, 2025 | MANESS, NICHOLAS JAMES | reporter.nih.gov |
| Evaluation of Memory Responses and Biomarkers from a Phase 1 Enterotoxigenic Escherichia coli (ETEC) Intramuscular Subunit Vaccine with dmLT Adjuvant | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $685,989 | May 24, 2021 | April 30, 2023 | NORTON, ELIZABETH B | reporter.nih.gov |
| IgM in the regulation of TB immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $685,810 | February 15, 2019 | September 15, 2021 | CHAN, JOHN R. | reporter.nih.gov |
| The Warburg effect and host immune response in tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $681,641 | June 6, 2017 | May 31, 2024 | SHI, LANBO | reporter.nih.gov |
| Nanovaccine-Mediated Immune Protection Against Influenza Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $680,912 | June 1, 2017 | May 31, 2023 | LEGGE, KEVIN L | reporter.nih.gov |
| Immunomodulatory Effects of Heterochiral Biomaterials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $677,486 | February 20, 2019 | October 31, 2023 | RUDRA, JAI | reporter.nih.gov |
| Modeling Mechanisms of Adjuvanted Influenza Vaccine Induced IgG Repertoire Diversity and Heterosubtypic Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $675,832 | February 1, 2017 | January 31, 2023 | ZAND, MARTIN S | reporter.nih.gov |
| The contribution of respiratory burst to antibiotic failure in Staphylococcus aureus bacteremia | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $674,578 | August 22, 2022 | July 31, 2024 | CONLON, BRIAN PATRICK | reporter.nih.gov |
| Dynamic learning for post-vaccine event prediction using temporal information in VAERS | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $669,017 | February 1, 2017 | January 31, 2024 | TAO, CUI | reporter.nih.gov |
| Quorum Sensing Regulation of EHEC Virulence Genes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $668,955 | July 1, 2003 | May 31, 2022 | SPERANDIO, VANESSA | reporter.nih.gov |
| The Impact of SARS-CoV-2 Immune Dysregulation on Antifungal Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $668,250 | August 5, 2022 | July 31, 2023 | LEAL, SIXTO MANUEL | reporter.nih.gov |
| The molecular basis of the carbapenem resistance epidemic | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $667,413 | August 1, 2019 | November 30, 2022 | KREISWIRTH, BARRY NEAL | reporter.nih.gov |
| Chemical disarming of drug resistance in Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $663,411 | July 16, 2018 | June 30, 2023 | STALLINGS, CHRISTINA LEIGH | reporter.nih.gov |
| Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $663,271 | February 15, 2017 | January 24, 2023 | ADHIKARI, RAJAN P | reporter.nih.gov |
| Non-invasive diagnosis of adult pulmonary tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $663,138 | April 1, 2019 | March 31, 2024 | CANGELOSI, GERARD A | reporter.nih.gov |
| Physiological and immunological responses to measles vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $661,557 | August 6, 2018 | July 31, 2023 | GRIFFIN, DIANE E | reporter.nih.gov |
| Development of IM Formulation of (2S,3S)-SPD for Nerve Agent Seizures | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $659,799 | August 15, 2019 | May 31, 2023 | ROGAWSKI, MICHAEL A. | reporter.nih.gov |
| Mechanisms of influenza transmission bottlenecks: impact on viral evolution | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $659,143 | January 1, 2017 | December 31, 2023 | FRIEDRICH, THOMAS C. | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Rbhs-New Jersey Medical School | Newark, NJ | 34 | $33.1 million | 0 | $0 |
| Washington University | Saint Louis, MO | 45 | $30.2 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 14 | $23.1 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 9 | $22.3 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 34 | $20.1 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 8 | $18.6 million | 0 | $0 |
| Duke University | Durham, NC | 24 | $18.5 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 10 | $17.9 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 28 | $17.4 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 20 | $16.7 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 5 | $15.1 million | 0 | $0 |
| Emory University | Atlanta, GA | 25 | $14.7 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 25 | $14.6 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 26 | $14 million | 0 | $0 |
| Yale University | New Haven, CT | 18 | $13.8 million | 0 | $0 |
| Steelworker Charitable/educational Org | Pittsburgh, PA | 1 | $13.4 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 29 | $13 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 18 | $12.8 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 12 | $12.6 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 18 | $12.4 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 26 | $12.4 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 23 | $12.1 million | 0 | $0 |
| University of Washington | Seattle, WA | 28 | $12 million | 0 | $0 |
| Colorado State University | Fort Collins, CO | 16 | $11.8 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 15 | $11.7 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 20 | $11.7 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 25 | $11.4 million | 0 | $0 |
| Stanford University | Stanford, CA | 21 | $10.5 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 23 | $10.5 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 22 | $10 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 12 | $9.8 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 16 | $9.7 million | 0 | $0 |
| Integrated Biotherapeutics, Inc. | Rockville, MD | 9 | $9.7 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 12 | $9.4 million | 0 | $0 |
| Cornell University | Ithaca, NY | 17 | $9.2 million | 0 | $0 |
| University of Chicago | Chicago, IL | 7 | $9 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 16 | $9 million | 0 | $0 |
| HDT Bio Corporation | Seattle, WA | 4 | $8.8 million | 0 | $0 |
| University of Florida | Gainesville, FL | 14 | $8.4 million | 0 | $0 |
| University of California at Davis | Davis, CA | 24 | $8.3 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 13 | $8.3 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 7 | $8.1 million | 0 | $0 |
| University of Montana | Missoula, MT | 4 | $8 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 11 | $7.8 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 13 | $7.8 million | 0 | $0 |
| University of Tennessee Health Sci CTR | Memphis, TN | 5 | $7.7 million | 0 | $0 |
| George Mason University | Fairfax, VA | 2 | $7.6 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 11 | $7.4 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 7 | $6.9 million | 0 | $0 |
| Ohio State University | Columbus, OH | 15 | $6.8 million | 0 | $0 |
| Arizona State University | Scottsdale, AZ | 5 | $6.7 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 9 | $6.6 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 19 | $6.5 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 9 | $6.1 million | 0 | $0 |
| University of Louisville | Louisville, KY | 5 | $5.9 million | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 19 | $5.8 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 12 | $5.7 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 11 | $5.7 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 8 | $5.6 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 10 | $5.3 million | 0 | $0 |
| Virginia Polytechnic Institute and State University | Blacksburg, VA | 16 | $5.3 million | 0 | $0 |
| Harvard Medical School | Boston, MA | 14 | $5.3 million | 0 | $0 |
| Southern Center for Environmental Justice Inc., Deep South Cente | New Orleans, LA | 1 | $4.9 million | 0 | $0 |
| Emergent Product Development Gaithersbur | Gaithersburg, MD | 3 | $4.8 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 11 | $4.7 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 9 | $4.6 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 9 | $4.6 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 8 | $4.4 million | 0 | $0 |
| Harvard University | Cambridge, MA | 2 | $4.3 million | 0 | $0 |
| University of Rochester | Rochester, NY | 8 | $4.2 million | 0 | $0 |
| Sound Pharmaceuticals, Inc. | Seattle, WA | 1 | $4.2 million | 0 | $0 |
| Meabco INC | Chicago, IL | 1 | $4.1 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 7 | $4 million | 0 | $0 |
| Trellis Bioscience, Inc. | Redwood City, CA | 2 | $4 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 10 | $4 million | 0 | $0 |
| Rutgers University New Brunswick | New Brunswick, NJ | 7 | $4 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 9 | $4 million | 0 | $0 |
| Therapyx, Inc. | Buffalo, NY | 2 | $3.9 million | 0 | $0 |
| Kansas State University | Manhattan, KS | 4 | $3.9 million | 0 | $0 |
| Hawaii Biotech, Inc. | Honolulu, HI | 2 | $3.9 million | 0 | $0 |
| Technical Resources International, Inc. | Bethesda, MD | 1 | $3.7 million | 0 | $0 |
| Wistar Institute | Philadelphia, PA | 2 | $3.7 million | 0 | $0 |
| SUNY at Stony Brook | Stony Brook, NY | 10 | $3.7 million | 0 | $0 |
| Microbiotix, INC | Worcester, MA | 5 | $3.6 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 3 | $3.6 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 7 | $3.6 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 10 | $3.4 million | 0 | $0 |
| Baebies, Inc. | Durham, NC | 2 | $3.3 million | 0 | $0 |
| Venatorx Pharmaceuticals, Inc. | Malvern, PA | 2 | $3.3 million | 0 | $0 |
| Novobiotic Pharmaceuticals, LLC | Cambridge, MA | 3 | $3.3 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 8 | $3.3 million | 0 | $0 |
| Battelle Memorial Institute | Columbus, OH | 1 | $3.2 million | 0 | $0 |
| Texas Biomedical Research Institute | San Antonio, TX | 7 | $3.2 million | 0 | $0 |
| University of Connecticut SCH of Med/dnt | Farmington, CT | 3 | $3.1 million | 0 | $0 |
| Rbhs-Robert Wood Johnson Medical School | Piscataway, NJ | 5 | $3 million | 0 | $0 |
| Curza INC | Salt Lake City, UT | 2 | $3 million | 0 | $0 |
| Enepret, Inc. | Lexington, KY | 1 | $3 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 10 | $3 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 7 | $2.9 million | 0 | $0 |
| Entasis Therapeutics, Inc. | Waltham, MA | 1 | $2.9 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 16 | $19,283,320 | 0 | $0 |
| 2024 | 21 | $20,108,115 | 0 | $0 |
| 2023 | 29 | $21,853,360 | 0 | $0 |
| 2022 | 963 | $415,438,934 | 0 | $0 |
| 2021 | 1,639 | $684,873,870 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 1,568 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 1,568 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-24-187 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 1,568 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.